Morphology of anorexigen-associated valve disease by transthoracic and transesophageal echocardiography

American Journal of Cardiology

Volumn 90, Issue 11, 2002, Pages 1269-1273

  Roldan, Carlos A ^b,c   Gelgand, Erika A ^a   Decker, Pamela ^a   Prasad, Arti ^a   Shively, Bruce K ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEVICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MITRAL VALVE REGURGITATION; PRIORITY JOURNAL; PULMONARY VALVE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE;

ADULT; AORTIC VALVE; APPETITE DEPRESSANTS; BODY MASS INDEX; DEXFENFLURAMINE; DRUG COMBINATIONS; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; FENFLURAMINE; HEART VALVE DISEASES; HUMANS; MIDDLE AGED; MITRAL VALVE; OBESITY; PHENTERMINE;

EID: 0036889731     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02852-7     Document Type: Article

References (19)

1. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.D., Edwards B.S., Edwards W.D., Schaff H.V. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337:1997;581-588.
2. Khan M.A., Herzog C.A., St. Peter J.V., Hartley G.G., Madlon-Kay R., Dick C.D., Asinger R.W., Vessey J.T. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite suppressant drugs. N Engl J Med. 339:1998;713-718.
3. Weissman N.J., Tighe J.F., Gottdiener J.S., Gwynne J.T., Sustained-Release Dexfenfluramine Study Group . An assessment of heart valve abnormalities in obese patients taking dexfenfluramine sustained-release dexfenfluramine or placebo. N Engl J Med. 339:1998;725-732.
4. Weissman N.J., Tighe J.F., Gottdiener J.S., Gwynne J.T. Prevalence of valvular regurgitation with dexfenfluramine three to five months after discontinuation of treatment. J Am Coll Cardiol. 34:1999;2088-2095.
5. Burger A.J., Sherman H.B., Charlamb M.J., Kim J., Asinas L.A., Flickner S.R., Blackburn G.L. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol. 34:1999;1153-1158.
6. Kancherla M.K., Salti H.I., Mulderink T.A., Parker M., Bonow R.O., Mehlman D.J. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. Am J Cardiol. 84:1999;1335-1338.
7. Shively B.K., Roldan C.A., Gill E.A., Najarian T., Loar S. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation. 100:1999;2161-2167.
8. Hensrud D.D., Connolly H.M., Grogan M., Miller F.A., Bailey K.R., Jensen M.D. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc. 74:1999;1191-1197.
9. Gardin J.M., Schumacher D., Constantine G., Davis K.D., Leung C., Reid C.L. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine/phentermine. JAMA. 283:2000;1703-1709.
10. Jollis J.G., Landolfo C.K., Kisslo J., Constantine G.D., Davis K.D., Ryan T. Fenfluramine and phentermine and cardiovascular findings. Effect of treatment duration on prevalence of valve abnormalities. Circulation. 101:2000;2071-2077.
11. Pellika P.A., Tajik A.J., Khanderia B.K., Seward J.B., Callahan J.A., Pitot H.C., Kvols L.K. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation. 87:1993;1188-1196.
12. Cannistra L.B., Davis S.M., Bauman A.G. Valvular heart disease associated with dexfenfluramine. N Engl J Med. 337:1997;636.
13. Benson C.T., Fugioka K., Rubenson D.S. An echocardiographic scoring algorithm for "carcinoid-like" valvular heart disease in patients treated with anorectic drugs. (abstr) J Am Coll Cardiol. 33:(suppl):1999;549A.
14. Kimmel S.E., Keane M.G., Crary J.L., Jones J., Kinman J.L., Beare J., Sammel M., Sutton M.S., Strom B.L. Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota. Am J Cardiol. 84:1999;304-308.
15. Jick H., Vasilakis C., Weinrauch L.A., Meier C.R., Jick S.S., Derby L.E. A population based study of appetite-suppressant drugs and the risk of cardiac valve regurgitation. N Engl J Med. 339:1998;719-724.
16. Wee C.C., Phillips R.S., Aurigemma G., Erban S., Kriegel G., Riley M., Douglas P.S. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med. 129:1998;870-874.
17. Singh J.P., Evans J.C., Levy D., Larson M.G., Freed L.A., Fuller D.L., Lehman B., Benjamin E.J. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (The Framingham Heart Study). Am J Cardiol. 83:1999;897-902.
18. Mohler E.R. III. Are atherosclerotic processes involved in aortic-valve calcification? Lancet. 356:2000;524-525.
19. Steeffee C.H., Singh H.K., Chitwood W.R. Histologic changes in three explanted native cardiac valves following use of fenfluramines. Cardiovasc Pathol. 8:1999;245-253.